Which is better, Dihexa or Semax?
Semax is graded human observational from Russian stroke studies without placebo control, which is weak but real human data. Dihexa is graded animal only, from one laboratory, with the HGF/c-Met mechanism paper retracted and the rat memory paper under an expression of concern, and no human safety data at all. On regulation, neither is on the 503A bulks list, but semax is covered by HHS's draft enforcement discretion policy (FDA's drug center recommended against listing; the advisory committee voted in favor, per HHS's Appendix B), while dihexa was not reviewed, is not covered, and has no federal basis to be compounded. [1] [2] [3] [4] [5] [6] [12]
How do Dihexa and Semax compare?
| Dimension | Dihexa | SemaxFavored |
|---|---|---|
| What it is [3] [7] | Synthetic oligopeptide derived from angiotensin IV (hexanoyl capped Tyr-Ile with an aminohexanoic amide tail). | Heptapeptide analog of ACTH fragment 4-10 with a stabilizing Pro-Gly-Pro tail. |
| Proposed mechanism [4] [7] | Reported to bind hepatocyte growth factor and potentiate c-Met signaling to drive synapse formation; the paper establishing this was retracted in 2025. | Raised hippocampal BDNF protein about 1.4 fold and trkB expression within hours of one intranasal dose in rats. |
| Human evidence [1] [2] [3] [8] | None. No human pharmacokinetic, safety, or efficacy study of any kind. | Open comparative Russian studies in acute ischemic stroke and chronic cerebrovascular insufficiency reporting faster recovery and fewer exacerbations; no blinding or placebo. |
| Data integrity [1] [3] [4] | Mechanism paper retracted (2025); design and rat memory paper under a 2021 expression of concern; no independent replication. | No retractions identified, but the clinical studies come from the developing research group and are published in Russian. |
| Theoretical safety concern [1] [9] | c-Met is an established oncogene, so potentiating it could plausibly promote tumor growth; no animal toxicology has been published. | Anxiety, irritability, insomnia, and nasal irritation reported; long term safety unknown. |
| Route [1] [3] | Oral or injected in rats; sold as capsules, powder, or transdermal products without absorption data. | Intranasal drops (Russian product and most sold forms). |
| FDA and compounding status [5] [6] [12] [13] | Nomination withdrawn: in no 503A category, not on the bulks list, not reviewed at the July 2026 PCAC meeting, and not covered by HHS's October 2026 draft enforcement discretion policy; no federal basis to compound it from bulk. | Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (intranasal only) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). Registered prescription drug in Russia. |
| WADA status [10] [11] | Prohibited at all times under S0 (non-approved substances). | Not named on the WADA Prohibited List; whether it falls under S0 (non-approved substances) is unclear, so tested athletes should confirm with their anti-doping organization. |
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | Dihexa | Semax |
|---|---|---|
| Class | Synthetic angiotensin IV derived oligopeptide (hexanoyl capped Tyr-Ile with an aminohexanoic amide tail), hepatocyte growth factor/c-Met potentiator | Synthetic heptapeptide analog of ACTH fragment 4-10 (Met-Glu-His-Phe-Pro-Gly-Pro), a melanocortin derived nootropic and neuroprotective peptide |
| What it is | Oral lab-made relative of the brain peptide angiotensin IV: rat memory data from one lab, a retracted mechanism paper, no human trials, no FDA approval. | Nasal peptide registered in Russia; rodent and Russian stroke trial data; not FDA approved; nasal use in HHS's October 2026 draft policy. |
| Evidence | Evidence: Animal-only evidence | Evidence: Human observational evidence |
| FDA status | Regulatory: Nomination withdrawn | Regulatory: HHS interim policy (draft) |
| Compounding | Dihexa has never been approved by FDA for any use. It was previously in 503A Category 2. FDA now lists dihexa acetate among nominations withdrawn by the nominators and notes that it has found no human exposure data. That places it in no 503A category and outside FDA's interim enforcement policy. FDA has said it will ask the Pharmacy Compounding Advisory Committee to consider dihexa acetate for the 503A bulks list at a meeting planned before the end of February 2027. As of the last verification date, no meeting date had been announced. Because it is not on that list, a 503A pharmacy has no federal basis to compound it, and no 503B pathway has been identified. | Semax is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 24, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds semax when every condition is met: a single active ingredient only (no blends or stacks), the allowed route (intranasal only), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add semax to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs. |
| WADA | WADA: WADA prohibited | WADA: WADA status unclear |
| Routes | Oral (rat studies; sold as capsules or powder), Intraperitoneal injection (rat studies), Transdermal and subcutaneous products exist without absorption data | Intranasal drops (Russian product and most sold forms), Subcutaneous injection (as sold, no published human data) |
| Typical cost | Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient semax on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. |
| Last verified |
Has Dihexa been tested directly against Semax?
No published trial has compared Dihexa and Semax directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do Dihexa and Semax cost?
| Dimension | Dihexa | Semax |
|---|---|---|
| Typical cost | Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient semax on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. |
| Price detail | Price index in progress | Semax price by channel |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the Dihexa page and the Semax page.
Frequently asked questions
Is dihexa stronger than semax?
There is no human evidence that dihexa does anything in people. Claims that it is far more potent than BDNF come from the inventing laboratory's rat and cell work, and the paper describing its mechanism was retracted in 2025. Semax has open label human stroke studies, though none were placebo controlled. [1] [3] [4]
Why was the dihexa paper retracted?
The 2014 journal article reporting that dihexa works through the HGF/c-Met system was retracted by the journal in April 2025, and the 2013 paper describing dihexa's design and rat memory effects carries a 2021 expression of concern. The mechanism should be treated as unconfirmed. [3] [4]
Can I get either one from a US pharmacy?
Semax possibly, under conditions; dihexa, no. Neither is on the 503A bulks list. Semax is covered by HHS's October 28, 2026 draft enforcement discretion policy, which says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (intranasal only) on a patient-specific prescription, when sourcing, testing, and adverse event reporting conditions are met. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. Dihexa is not covered and has no federal basis to be compounded: its nomination was withdrawn and it is not on the bulks list. State law still applies. [5] [6] [12] [13]
Does dihexa carry a cancer risk?
Possibly, in theory. Dihexa is proposed to boost signaling through c-Met, a receptor that drives several cancers and is the target of approved cancer drugs. No toxicology study in animals or safety study in humans has been published to test this. [3] [9]
Are they allowed in sport?
Dihexa is prohibited at all times under S0 as a non-approved substance. Semax is not named on the list, but S0 could apply, so tested athletes should confirm with their anti-doping organization. [10] [11]
Conditions studied
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Gusev EI et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova 1997PubMed 11517472, 1997
- [2]Gusev EI et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2018PubMed 29798983, 2018
- [3]McCoy AT et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther 2013 (expression of concern 2021)PubMed 23055539, 2013
- [4]Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther 2014 (retracted April 2025)PubMed 25187433, 2014
- [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [6]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [7]Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res 2006PubMed 16996037, 2006
- [8]Gusev EI et al. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova 2005PubMed 15792140, 2005
- [9]Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease. J Alzheimers Dis 2015 (review by the developers)PubMed 25649658, 2015
- [10]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). Dihexa vs Semax: evidence, cost, and legality. https://peptideagent.ai/compare/dihexa-vs-semax- HTML link
<a href="https://peptideagent.ai/compare/dihexa-vs-semax">Dihexa vs Semax: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.